Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 197 resultater
Tid
Selskap
Tittel
Sektor
Kategori
16 May 2024
22:00 CEST
INVENTIVA
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
20103010 Biotechnology
Other subject
16 May 2024
22:00 CEST
INVENTIVA
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
20103010 Biotechnology
Other subject
13 May 2024
08:30 CEST
INVENTIVA
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité
20103010 Biotechnology
Other subject
13 May 2024
08:30 CEST
INVENTIVA
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
20103010 Biotechnology
Other subject
03 Apr 2024
22:00 CEST
INVENTIVA
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
20103010 Biotechnology
Other subject
03 Apr 2024
22:00 CEST
INVENTIVA
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
20103010 Biotechnology
Other subject
28 Mar 2024
08:00 CET
INVENTIVA
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
20103010 Biotechnology
Other subject
28 Mar 2024
08:00 CET
INVENTIVA
Inventiva announces the nomination of Andre Turenne as Director
20103010 Biotechnology
Other subject
27 Mar 2024
21:00 CET
INVENTIVA
Inventiva publie ses résultats annuels 2023
20103010 Biotechnology
Other subject
27 Mar 2024
21:00 CET
INVENTIVA
Inventiva reports its 2023 full-year results
20103010 Biotechnology
Other subject
22 Mar 2024
21:00 CET
INVENTIVA
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
20103010 Biotechnology
Other subject
22 Mar 2024
21:00 CET
INVENTIVA
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023
20103010 Biotechnology
Other subject
18 Mar 2024
21:00 CET
INVENTIVA
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
20103010 Biotechnology
Other subject
18 Mar 2024
21:00 CET
INVENTIVA
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
20103010 Biotechnology
Other subject
13 Mar 2024
21:00 CET
INVENTIVA
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
20103010 Biotechnology
Other subject
13 Mar 2024
21:00 CET
INVENTIVA
Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2
20103010 Biotechnology
Other subject
07 Mar 2024
22:00 CET
INVENTIVA
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
20103010 Biotechnology
New
07 Mar 2024
22:00 CET
INVENTIVA
Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH
20103010 Biotechnology
New
15 Feb 2024
22:35 CET
INVENTIVA
Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3
20103010 Biotechnology
Other subject
15 Feb 2024
22:35 CET
INVENTIVA
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
20103010 Biotechnology
Other subject
24 Jan 2024
22:15 CET
INVENTIVA
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
20103010 Biotechnology
Other subject
24 Jan 2024
22:15 CET
INVENTIVA
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
20103010 Biotechnology
Other subject
10 Jan 2024
22:00 CET
INVENTIVA
Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement
20103010 Biotechnology
Other subject
10 Jan 2024
22:00 CET
INVENTIVA
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
20103010 Biotechnology
Other subject
20 Dec 2023
22:00 CET
INVENTIVA
Inventiva annonce la randomisation du premier patient en Chine dans l’étude clinique NATiV3 et fait le point sur son programme de développement clinique
20103010 Biotechnology
Other subject
20 Dec 2023
22:00 CET
INVENTIVA
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
20103010 Biotechnology
Other subject
04 Dec 2023
22:05 CET
INVENTIVA
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
20103010 Biotechnology
Other subject
04 Dec 2023
22:05 CET
INVENTIVA
Inventiva annonce la recommandation positive du troisième DMC de l’étude clinique de Phase III avec lanifibranor dans la NASH
20103010 Biotechnology
Other subject
21 Nov 2023
22:00 CET
INVENTIVA
Inventiva reports 2023 Third Quarter Financial Information¹
20103010 Biotechnology
Other subject
21 Nov 2023
22:00 CET
INVENTIVA
Inventiva publie ses informations financières du 3ème trimestre 2023¹
20103010 Biotechnology
Other subject
06 Nov 2023
22:00 CET
INVENTIVA
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
20103010 Biotechnology
Other subject
06 Nov 2023
22:00 CET
INVENTIVA
Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD
20103010 Biotechnology
Other subject
28 Sep 2023
22:00 CEST
INVENTIVA
Inventiva reports its 2023 first-half financial results and provides a corporate update
20103010 Biotechnology
Other subject
28 Sep 2023
22:00 CEST
INVENTIVA
Inventiva publie ses résultats financiers du 1er semestre 2023 et fait un point sur ses activités
20103010 Biotechnology
Other subject
20 Sep 2023
22:00 CEST
INVENTIVA
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20103010 Biotechnology
Alliances and agreements
20 Sep 2023
22:00 CEST
INVENTIVA
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20103010 Biotechnology
Alliances and agreements
31 Aug 2023
07:30 CEST
INVENTIVA
Inventiva annonce un financement d'environ 35,7 millions d'euros auprès d'investisseurs nouveaux et existants, constitué d'une augmentation de capital réservée de 30,6 millions d'euros et d'une émission de certificats de royalties de 5,1 mi
20103010 Biotechnology
Other financial transaction
31 Aug 2023
07:30 CEST
INVENTIVA
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
20103010 Biotechnology
Other financial transaction
27 Jul 2023
22:33 CEST
INVENTIVA
Correction: Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
20103010 Biotechnology
Other subject
27 Jul 2023
22:33 CEST
INVENTIVA
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
20103010 Biotechnology
Other subject
27 Jul 2023
22:00 CEST
INVENTIVA
Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
20103010 Biotechnology
Other subject
27 Jul 2023
22:00 CEST
INVENTIVA
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
20103010 Biotechnology
Other subject
24 Jun 2023
08:00 CEST
INVENTIVA
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
20103010 Biotechnology
Other subject
24 Jun 2023
08:00 CEST
INVENTIVA
Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association
20103010 Biotechnology
Other subject
13 Jun 2023
23:00 CEST
INVENTIVA
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
20103010 Biotechnology
Other subject
13 Jun 2023
23:00 CEST
INVENTIVA
Inventiva annonce les résultats positifs de l’étude clinique initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et NAFLD
20103010 Biotechnology
Other subject
08 Jun 2023
08:30 CEST
INVENTIVA
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
20103010 Biotechnology
Other subject
08 Jun 2023
08:30 CEST
INVENTIVA
Inventiva et Echosens lancent une initiative conjointe pour mieux sensibiliser l’opinion à la NASH et faciliter l’accès au dépistage pour les patients à risque
20103010 Biotechnology
Other subject
07 Jun 2023
22:00 CEST
INVENTIVA
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
20103010 Biotechnology
Other subject
07 Jun 2023
22:00 CEST
INVENTIVA
Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva